Ranirestat

Drug Profile

Ranirestat

Alternative Names: AS-3201; SX-3030; SX-3202

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Eisai Co Ltd; Sumitomo Dainippon Pharma
  • Class Antihyperglycaemics; Pyrazines; Small molecules; Spiro compounds
  • Mechanism of Action Aldehyde reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diabetic neuropathies

Most Recent Events

  • 20 May 2015 Ranirestat is still in phase III trials for Diabetic neuropathies in Japan
  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
  • 07 Feb 2013 Eisai completes a phase II/III trial in Diabetic neuropathies in USA, United Kingdom, Belgium, Estonia, Hungary and India (NCT00927914)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top